Latest News for TCRT
Alaunos Therapeutics Inc. (NASDAQ: TCRT) shares are down on Monday after the company announced preclinical proof-of-concept data for its lead drug candidate, ALN1003.
Alaunos' ALN1003 shows dose dependent weight loss, better body composition, reduced liver weight, and improved liver biomarkers in preclinical studies.
Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 44,597 shares, a decline of 14.6% from the January 15th total of 52,250 shares. Based on an average daily trading volume, of 15,766 shares, the short-interest ratio is currently
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TCRT.
U.S. House Trading
No House trades found for TCRT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.